The $8M license commitment is material relative to Accuray's $29M market cap, but the collaboration is a long-term product integration play with no near-term revenue catalyst. Monitor for future announcements on commercial adoption of the online adaptive solution and any impact on Accuray's cash position or operating expenses.
Price Chart
Executive Summary
Accuray entered a definitive collaboration agreement with RaySearch Laboratories to integrate RayStation treatment planning software with Accuray's Radixact and CyberKnife platforms, aiming to accelerate online adaptive radiation therapy capabilities. Accuray agreed to purchase $8 million in RayStation licenses to support commercialization, with joint marketing and support. For a company with a $29M market cap, this $8M commitment represents a material investment, but the deal is a partnership/licensing agreement, not a transformative M&A event, and no financial impact on Accuray's revenue or earnings is disclosed.
Key Financial Metrics
Key Facts
- Accuray and RaySearch entered a definitive agreement for an expanded collaboration on online adaptive radiation therapy.
- Accuray agreed to purchase specified RayStation licenses with a total order value of $8 million.
- Initial focus is on Accuray's Radixact platform, with future extension to CyberKnife.
- The collaboration combines Accuray's photon-based platforms and imaging with RaySearch's treatment planning and workflow software.
- No financial terms beyond the $8M license purchase were disclosed; no revenue, earnings, or guidance changes were provided.
Financial Impact
Accuray committed $8 million to purchase RayStation licenses; no other financial terms disclosed.
Risk Factors
- The $8M license purchase may strain Accuray's cash reserves given its small market cap.
- No revenue or earnings guidance was provided; the collaboration's financial impact is uncertain.
- Integration and regulatory clearance risks could delay commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302876539 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Press Release | $0.1340 | awaiting T+5 | — | $0.1300 (−2.99%) |
Oct 16, 2026 10d ago | DEF 14A | $0.1400 $0.1250 | ▲ +10.71% | ▲ +10.57% | $0.1300 (+7.14%) |
Oct 13, 2026 13d ago | 8-K | $0.1751 $0.1370 | ▼ −21.76% | ▼ −22.21% | $0.1300 (−25.76%) |
Oct 7, 2026 19d ago | 3 | $0.2414 $0.1738 | ▼ −28.00% | ▼ −27.73% | $0.1300 (−46.15%) |
Oct 6, 2026 20d ago | 8-K | $0.2534 $0.1751 | ▲ +30.90% | ▲ +29.92% | $0.1300 (+48.70%) |
Sep 27, 2026 29d ago | Press Release | $0.2998 $0.3017 | ▲ +0.63% | ▼ −0.57% | $0.1300 (−56.64%) |
Sep 22, 2026 4w ago | Institutional Cluster | $0.2300 $0.3000 | ▲ +30.43% | ▲ +31.62% | $0.1300 (−43.48%) |
Sep 14, 2026 6w ago | EFFECT | $0.2453 $0.2400 | ▲ +2.16% | ▲ +2.27% | $0.1300 (+47.00%) |
Sep 11, 2026 6w ago | Press Release | $0.2502 $0.2336 | ▼ −6.63% | ▼ −6.41% | $0.1300 (−48.04%) |
Aug 19, 2026 9w ago | Press Release | $0.2924 $0.2621 | ▲ +10.36% | ▲ +11.48% | $0.1300 (+55.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers